Comment in Response to Proposed Rulemaking: Regulation to Require Drug Pricing Transparency
Letters • 2018On October 18, 2018, the Trump Administration proposed regulations at the Centers for Medicare and Medicaid Services (CMS) to require publication of the list price of any prescription drug or biological product paid by Medicare or Medicaid in direct-to-consumer (DTC) advertising. While TAG applauds the administration's attention to curbing drastic increases in drug prices, list price transparency in DTC advertisements alone will not be a sufficient measure to bring necessary change.
Global HCV Elimination Targets and Challenges: An Interview with Andrew Hill
TAGline • 2018By Bryn Gay & Annette Gaudino Are we on track with WHO targets[1,2] to eliminate the hepatitis C virus (HCV) by 2030? Andrew Hill, Senior Research Fellow, Liverpool University unveils powerful research that compares 91 countries’ data on HCV prevalence, diagnosis, treatment, and income level. One central concern is that annually treating an estimated 1.42…
In a State of Disunion: HIV, TB, and HCV Elimination Policies and Priorities Under the Trump Administration
TAGline • 2018By Suraj Madoori During Trump’s first-ever State of the Union address on January 30, activists observed a dearth of clear priorities to eliminate HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the U.S. Science and longstanding bipartisan interest in global health have paved the way for potential monumental political wins by the Trump administration:…
A Pharma View on Delinkage and New Models for Biomedical Innovation: An Interview with Marc Destito from Otsuka Pharmaceutical
TAGline • 2018by Mike Frick and Lindsay McKenna, TB Project Co-Directors, TAG In an interview with TAG’s Tuberculosis (TB) Project, Marc Destito, Senior Director of Public Affairs and Global Alliance Management at Otsuka Pharmaceutical, provides insight into how the development of TB drug delamanid moved the company closer to the principle of delinkage, an approach to biomedical…
Pharma Lies, People Die: Myth-Busting Fact Sheet on Medicine Development and Pricing
TAGline • 2018By Bryn Gay, HCV Project Director, TAG and Claudine Guerra, CUNY DOWNLOAD to print this article as a poster (A1 size) The current leaders of the United States manufacture crises, media optics, and catchy sound bites to side step actual responsibility for tackling immensely complex policy issues like extortionately high prescription drug prices. The American…
Beyond Declarations: Lessons from the UN High-Level Meeting on TB on Building and Transforming Political Will into Real Access to Medicines
TAGline • 2018By Khairunisa Suleiman, Technical Co-Lead, Global TB CAB and Suraj Madoori, U.S. and Global Health Policy Director, TAG On Sept. 26, 2018, the world came together at the United Nations General Assembly in New York for the first-ever High-Level Meeting on Tuberculosis (TB HLM), bringing hope for new political will and resources to jump-start the…
The HCV Diagnostics Pipeline
Pipeline • 2018July 2018 by Bryn Gay Simpler Rapid, Point-of-Care Hepatitis C Diagnostics: Are We There Yet?1 To increase treatment rates and make a dent in the epidemic by 2030, countries need to scale up access to affordable, simple, rapid diagnostics, ensuring services reach people most at risk of HCV infection, including people who inject or use…
White House and Congress Must Boldly Address Drug Pricing and Ensure Access to Critical HIV, HCV, and TB Medications
Letters • 2018Treatment Action Group (TAG), NASTAD (National Alliance of State & Territorial AIDS Directors) and HIVMA (HIV Medicine Association join together in submitting collaborative comments today in response to the Department of Health and Human Services (HHS) public request for information (RFI) on the agency’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
The Role of Vaccines and Cures in HIV Elimination
TAGline • 2018By Richard Jefferys The development of highly effective approaches to HIV treatment and prevention—in the form of combination antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP)—stands among the most impressive scientific achievements in human history. As detailed elsewhere in this issue of TAGline, the widespread implementation of these interventions has the potential, at least theoretically, to…
NY State Medicaid Director Announces Potential Path for Volume Based Deal to Expand Hepatitis C Treatment at Lower Price
Statement / Press • 2018On Monday, February 12th, New York State Medicaid Director Jason Helgerson made news by announcing a potential path forward in the State’s response to its major hepatitis C epidemic at the joint Senate/Assembly budget hearing on Health and Medicaid.